{"schema_version":"secwatch.filing_event.v1","accession":"0001937653-24-000027","form_type":"8-K","ticker":"ZYME","cik":"0001937653","company_name":"Zymeworks Inc.","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.256456+00:00","generated_at":"2026-06-03T00:57:08.561106+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Zymeworks Q1 net loss $31.7M, revenue $10M; cash $420.5M, runway into 2H27","bullets":["Revenue fell to $10.0M from $35.6M YoY due to transfer of zanidatamab responsibilities to Jazz.","Net loss widened to $31.7M vs $24.4M in Q1 2023; R&D expense decreased 30% to $32.0M.","Cash resources $420.5M; combined with anticipated milestones, funded into 2H 2027.","Partner Jazz completed rolling BLA submission to FDA for zanidatamab in BTC; Phase 3 breast cancer trial planned H2 2024.","On track for two IND submissions in 2024 for ZW191 and ZW171; Dr. Neil Gallagher joined board."],"urls":{"canonical":"https://secwatch.observer/filing/0001937653-24-000027","json":"https://secwatch.observer/filing/0001937653-24-000027.json","markdown":"https://secwatch.observer/filing/0001937653-24-000027.md","text":"https://secwatch.observer/filing/0001937653-24-000027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1937653/000193765324000027/0001937653-24-000027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1937653/000193765324000027/zyme-20240502.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T00:57:08.561106+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"54ee1b69c8ebb9838167703e3820a4fde76f83d1","claim":"Zymeworks Inc. reported three months ended March 31, 2024 results: revenue $10.0 million.","evidence_excerpt":"Revenue was $10.0 million for the three months ended March 31, 2024 compared to $35.6 million for the same period in 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1937653/000193765324000027/0001937653-24-000027-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended March 31, 2024"},{"label":"Revenue","value":"$10.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}